Read more in the study ‘The impact of Covid-19 on access to Parkinson’s disease medication’.
Has Covid-19 impacted access to Parkinson’s medication?
Author: Simge Eva DoganPublished: 17 September 2020
Prep: Cook: Serves:
New research has found that the coronavirus pandemic has affected access to medication for people living with Parkinson’s disease.
The sub-study used information from a survey conducted by the International Parkinson and Movement Disorder Society. The results from 346 participants showed that 22.8% of high-income and 88.9% of low-income countries’ respondents agreed that the coronavirus crisis had impacted people’s access to Parkinson’s medication. Some respondents reported increased disability, increased hospitalisation and increased mortality as factors. The majority of those who completed the survey were doctors.
The researchers concluded: “Our results offer preliminary data that the Covid-19 pandemic has affected Parkinson’s disease patients’ access to regular medication.
“Covid-19 has diverted resources away from chronic conditions towards the fight against Covid-19 in many countries. Resource-poor countries seem to be disproportionately affected compared to their affluent counterparts.”
For more information on Parkinson’s and Covid-19 please visit the EPDA website.
Share this story
Bill Bucklew on walking 2,500 miles for Parkinson’s
Bill Bucklew tells us why he's not afraid of failureREAD MORE
Emma Lawton launches crowdfunding campaign for Parkinson’s video website
Help fund peer-led support websites ‘threesixfives’READ MORE
Parkinson’s podcasts promise ‘new perspectives on latest science’
A new series of monthly Parkinson’s podcasts kicks offREAD MORE